The angiotensin-converting enzyme (ACE) inhibitor and angiotensin II (Ang II) type I receptor (AT1R) blocker are part of therapeutics for combating CKD progression, as circulating Ang II is reported to promote EC dysfunction and hypertension as well as extracellular matrix (ECM) dysregulation [3]. The gene discussed is ACE; the disease is chronic kidney disease.